UPDATE: Piper Jaffray Upgrades Threshold Pharmaceuticals to Overweight on Product Differentiation
Piper Jaffray upgraded Threshold Pharmaceuticals (NASDAQ: THLD) from Neutral to Overweight and raised the price target from $5.00 to $10.00.
Piper Jaffray noted, "We are upgrading our THLD rating to OW as a result of diligence on the differentiation of TH-302 (‘302) in 1st-line soft tissue sarcoma (STS) relative to mind-share competitor's palifosfamide (pali', Ziopharm). We believe that near-term data will enhance conviction on the broad applicability of Threshold's hypoxia-activation platform for targeting a wide range of cancer indications with the potential to substantively add/extend efficacy over standard chemotherapy (CTx). We perceive the current trading range of THLD shares to present a valuation discrepancy relative to peers and THLD's pipeline value."
Threshold Pharmaceuticals closed at $4.46 on Tuesday.
Latest Ratings for THLD
|Sep 2014||Cantor Fitzgerald||Initiates Coverage on||Buy|
|Sep 2014||HC Wainwright||Initiates Coverage on||Buy|
|Feb 2013||Piper Jaffray||Upgrades||Neutral||Overweight|
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.